Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2022 | 1623 | 1.210 |
Why?
|
| Nuclear Receptor Coactivator 3 | 5 | 2021 | 351 | 1.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 2123 | 0.960 |
Why?
|
| Tumor Hypoxia | 1 | 2024 | 6 | 0.890 |
Why?
|
| Photoacoustic Techniques | 1 | 2024 | 11 | 0.880 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 690 | 0.870 |
Why?
|
| Glutamine | 2 | 2022 | 222 | 0.810 |
Why?
|
| Bone Neoplasms | 3 | 2024 | 446 | 0.790 |
Why?
|
| Cell Plasticity | 1 | 2022 | 36 | 0.770 |
Why?
|
| Sirtuin 3 | 1 | 2020 | 10 | 0.700 |
Why?
|
| Aconitate Hydratase | 1 | 2020 | 13 | 0.690 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 2768 | 0.690 |
Why?
|
| Transcriptional Activation | 3 | 2018 | 499 | 0.620 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 746 | 0.620 |
Why?
|
| Phosphofructokinase-2 | 1 | 2018 | 24 | 0.580 |
Why?
|
| Nuclear Receptor Coactivator 2 | 3 | 2015 | 211 | 0.540 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 716 | 0.520 |
Why?
|
| Glucose | 2 | 2018 | 925 | 0.500 |
Why?
|
| Cell Movement | 5 | 2018 | 917 | 0.500 |
Why?
|
| Cell Line, Tumor | 13 | 2025 | 3758 | 0.480 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1717 | 0.480 |
Why?
|
| Mitochondria | 1 | 2020 | 744 | 0.470 |
Why?
|
| Neoplasms | 2 | 2022 | 3029 | 0.420 |
Why?
|
| Transcription, Genetic | 4 | 2015 | 1758 | 0.410 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2013 | 76 | 0.400 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2022 | 382 | 0.370 |
Why?
|
| Energy Metabolism | 2 | 2015 | 813 | 0.370 |
Why?
|
| Annexin A2 | 3 | 2019 | 4 | 0.370 |
Why?
|
| Protein Prenylation | 1 | 2011 | 10 | 0.370 |
Why?
|
| Pseudopodia | 1 | 2011 | 9 | 0.360 |
Why?
|
| Reproduction | 1 | 2013 | 245 | 0.360 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 592 | 0.350 |
Why?
|
| Mice | 14 | 2025 | 18962 | 0.350 |
Why?
|
| Glycolysis | 2 | 2022 | 172 | 0.320 |
Why?
|
| Animals | 17 | 2025 | 36441 | 0.310 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 267 | 0.310 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 2658 | 0.310 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 1783 | 0.310 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2023 | 98 | 0.300 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 433 | 0.300 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 1006 | 0.300 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 822 | 0.300 |
Why?
|
| Receptors, Estrogen | 2 | 2024 | 829 | 0.280 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2554 | 0.280 |
Why?
|
| Phosphorylation | 5 | 2018 | 1707 | 0.260 |
Why?
|
| Mice, Nude | 2 | 2020 | 777 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 669 | 0.240 |
Why?
|
| IMP Dehydrogenase | 1 | 2025 | 27 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2014 | 2715 | 0.220 |
Why?
|
| Doxorubicin | 1 | 2025 | 300 | 0.210 |
Why?
|
| TNF Receptor-Associated Factor 4 | 2 | 2023 | 18 | 0.200 |
Why?
|
| Humans | 23 | 2025 | 133772 | 0.200 |
Why?
|
| Circadian Rhythm | 2 | 2015 | 298 | 0.190 |
Why?
|
| Citric Acid Cycle | 1 | 2022 | 49 | 0.190 |
Why?
|
| Cell Membrane | 2 | 2015 | 487 | 0.180 |
Why?
|
| Mice, SCID | 3 | 2018 | 613 | 0.170 |
Why?
|
| Genes, myc | 1 | 2019 | 107 | 0.160 |
Why?
|
| Castration | 1 | 2019 | 33 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2024 | 1004 | 0.150 |
Why?
|
| Metabolomics | 1 | 2022 | 456 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1103 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 247 | 0.150 |
Why?
|
| Receptor, trkA | 1 | 2018 | 18 | 0.150 |
Why?
|
| Phosphoserine | 1 | 2018 | 42 | 0.150 |
Why?
|
| Transketolase | 1 | 2018 | 19 | 0.150 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 35 | 0.150 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 44 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 399 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 119 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 271 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 165 | 0.140 |
Why?
|
| Prognosis | 4 | 2025 | 5074 | 0.140 |
Why?
|
| Hexosamines | 1 | 2016 | 17 | 0.130 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 392 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2019 | 2902 | 0.130 |
Why?
|
| RNA Interference | 1 | 2018 | 544 | 0.130 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2015 | 12 | 0.120 |
Why?
|
| Male | 12 | 2023 | 65893 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2015 | 23 | 0.120 |
Why?
|
| E2F1 Transcription Factor | 1 | 2016 | 51 | 0.120 |
Why?
|
| Protein Binding | 3 | 2015 | 1847 | 0.120 |
Why?
|
| Female | 9 | 2025 | 71654 | 0.120 |
Why?
|
| Lipogenesis | 1 | 2015 | 59 | 0.110 |
Why?
|
| Protein Transport | 2 | 2015 | 388 | 0.110 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 467 | 0.110 |
Why?
|
| Gene Expression | 2 | 2015 | 1616 | 0.110 |
Why?
|
| Mouth Neoplasms | 1 | 2015 | 115 | 0.110 |
Why?
|
| Apoptosis | 1 | 2020 | 1937 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 218 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2015 | 834 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 732 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1313 | 0.100 |
Why?
|
| Cell Survival | 1 | 2015 | 889 | 0.100 |
Why?
|
| DNA | 2 | 2016 | 1678 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 559 | 0.090 |
Why?
|
| Chromatin | 1 | 2015 | 614 | 0.090 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2011 | 19 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2013 | 871 | 0.090 |
Why?
|
| Metabolome | 1 | 2014 | 312 | 0.090 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 96 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2011 | 51 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 747 | 0.090 |
Why?
|
| Liver | 2 | 2015 | 1877 | 0.090 |
Why?
|
| Ubiquitination | 2 | 2023 | 183 | 0.080 |
Why?
|
| STAT6 Transcription Factor | 1 | 2010 | 38 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2019 | 4912 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2014 | 950 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2789 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2019 | 907 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3971 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 396 | 0.060 |
Why?
|
| ARNTL Transcription Factors | 2 | 2015 | 42 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2019 | 482 | 0.060 |
Why?
|
| Disease Progression | 3 | 2019 | 2240 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 508 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 717 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 133 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2024 | 310 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2022 | 164 | 0.040 |
Why?
|
| Androgens | 1 | 2023 | 297 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2021 | 3994 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2019 | 457 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 199 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 318 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 1044 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 972 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2015 | 18 | 0.030 |
Why?
|
| Glucokinase | 1 | 2015 | 16 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 90 | 0.030 |
Why?
|
| DNA Repair | 1 | 2019 | 632 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2015 | 89 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1596 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 3036 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2015 | 211 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1388 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 149 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 197 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 189 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 351 | 0.030 |
Why?
|
| CLOCK Proteins | 1 | 2014 | 31 | 0.030 |
Why?
|
| DNA Replication | 1 | 2016 | 363 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 307 | 0.030 |
Why?
|
| Cadherins | 1 | 2014 | 186 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 626 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 248 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 444 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1378 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1571 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1145 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2844 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2010 | 68 | 0.020 |
Why?
|
| Models, Biological | 1 | 2015 | 1535 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 148 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 248 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5195 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 29318 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 336 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 873 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 716 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1137 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1850 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 17433 | 0.010 |
Why?
|